Mi QUIT CARE (Mile Square QUIT Community-Access-Referral-Expansion)
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Mar 29, 2021
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The Mi QUIT CARE trial is studying how different messages about quitting smoking can help patients decide to receive support from a smoking cessation coach at the Illinois Tobacco Quitline. Specifically, the trial is comparing two types of messages: one that encourages patients to choose to connect with a coach and another that simply provides information. The researchers want to see which message is more effective in getting patients to speak with a Quitline coach about quitting smoking.
To participate in this trial, you need to be at least 18 years old, currently smoke, speak English, and be a patient at Mile Square Health Center. If you join the study, you will receive messages through a patient portal about quitting smoking. The trial will look at how many patients respond to these messages, how effective they are in encouraging people to get help, and if using the patient portal is a cost-effective way to support smoking cessation. Your involvement could help improve how healthcare providers assist patients in quitting smoking.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged 18 years and older
- • current smoker
- • English speaking
- • Patient at Mile Square Health Center (Main, Englewood, South Shore, Auburn Gresham, Cicero, Back of the Yards)
- Exclusion Criteria:
- • aged less than 18
- • non-smoker
- • non English speaking
- • Not a patient at MSHC
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Rachel Caskey, MD, MaPP
Principal Investigator
University of Illinois Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials